Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Overweight 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Metabolic Syndrome 1 Melanoma 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

pembrolizumab 254 Nivolumab 232 Ipilimumab 210 aldesleukin 119 Cyclophosphamide 117 Interleukin-2 88 trametinib 74 dabrafenib 66 Dacarbazine 62 Vemurafenib 60 fludarabine 59 Temozolomide 59 fludarabine phosphate 52 Biopsy 43 Radiosurgery 41 sargramostim 39 Bevacizumab 39 incomplete Freund's adjuvant 35 binimetinib 34 Paclitaxel 32 Magnetic Resonance Spectroscopy 32 atezolizumab 31 Specimen Handling 31 Radiotherapy 31 Cisplatin 31 Introns 30 cobimetinib 29 Blood Specimen Collection 29 encorafenib 28 Carboplatin 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡